Enasidenib

Enasidenib
Clinical data
Trade names	Idhifa
Other names	AG-221
AHFS/Drugs.com	Monograph
MedlinePlus	a617040
License data	US DailyMed: Enasidenib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01XX59 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Identifiers
CAS Number	1446502-11-9;
PubChem CID	89683805;
DrugBank	DB13874;
ChemSpider	38772329;
UNII	3T1SS4E7AG;
KEGG	D10901; as salt: D11044;
ChEBI	CHEBI:145374;
ChEMBL	ChEMBL3989908;
PDB ligand	69Q (PDBe, RCSB PDB);
Chemical and physical data
Formula	C19H17F6N7O
Molar mass	473.383 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(CNC1=NC(=NC(=N1)NC2=CC(=NC=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F)O;
	InChI InChI=InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32); Key:DYLUUSLLRIQKOE-UHFFFAOYSA-N;

Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development.

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.